• Long-term Study Supports Link Between Inflammation and Cognitive Problems in Older Breast Cancer Survivors

    Scientists are still trying to understand why many breast cancer survivors experience troubling cognitive problems for years after treatment. Inflammation is one possible culprit. A new long-term study of older breast cancer survivors, published today in the Journal of Clinical Oncology, adds important evidence to that potential link.

    Category: Story

  • Healthy Aging Symposium Promotes Collaboration Across Disciplines

    With more than 300 registrants in person and via Zoom, the first annual Healthy Aging Symposium at Georgetown brought together students, faculty, researchers and those who work in the field of aging for panel discussions, poster presentations and networking.

    Category: Story

  • Healthy Aging Symposium

    Plan to attend the first annual symposium focused on aging. This event is free and open to all members of the Georgetown community and our community collaborators and partners.

    Presenters will be addressing critical issues in aging research, policy and care from cells to society and include transdisciplinary researchers from several Georgetown Schools, cross-campus programs, community groups, MedStar Health and the NIH.

    Our goal is to have attendees get to know others interested in aging, describe resources, and stimulate people coming together to form new teams to address challenges of an aging society.

    Categories: Events, Story

  • Studies of Cytosolic DNAs in the Interactions of Aging Hallmarks (R01 Clinical Trial Not Allowed) – RFA-AG-23-015

    The accumulation of DNA in the cytosol (the fluid portion of a cell’s cytoplasm) has important associations with aging, cellular senescence, and decline of cellular and physiological functions. The goal of this FOA is to explore cytosolic DNAs as integrators of hallmark interactions and instigators of downstream events leading to age-related cellular and tissue deterioration. Deadline October 11, 2022.

    Category: Funding

  • Mapping Interconnectivity Among Hallmarks of Aging Under Lifespan Modifications (R01 Clinical Trial Not Allowed) – RFA-AG-23-013

    This FOA is designed to discover whether there are hierarchies among the hallmarks that underlie different changes with age, or if there is a threshold beyond which the hallmarks and/or their interactions with one another become “tipping points” that beyond which the aging process cannot be reversed. Deadline October 11, 2022.

    Category: Funding

  • Inter-Organelle Communication as a Platform to Interrogate the Interactions of Hallmarks of Aging (R01 Clinical Trial Not Allowed) – RFA-AG-23-012

    Contact sites where the membranes of cell organelles come together are critical hubs for the transfer of ions, metabolites, lipids, and proteins that have important roles in cellular aging. This FOA aims to deepen our mechanistic understanding of organelle communication and how it shapes the interactions of the hallmarks of aging. Deadline October 11, 2022.

    Category: Funding

  • Research Reveals How Aging Cells Can Be an Underlying Cause of Kidney Damage

    A study in mice by researchers at Georgetown Lombardi Comprehensive Cancer Center has found that stress and tissue damage initiated by angiotensin II, a molecule that is known to increase blood pressure and stiffening in the linings of blood vessels, leads to cellular senescence, a process by which a cell ages and permanently stops dividing but does not die. Importantly, when the researchers eliminated senescent cells from the mice, tissues returned to a normal state in spite of a continued infusion of angiotensin II.

    Category: Story Tag:

  • Reducing your risk of cognitive disease: A $12M research study, 60 years in the making

    A McCourt researcher has dedicated her career to aging research and a decades-old study, revealing a non-medical intervention that proves resilient against dementia.

    Category: Story

  • Trial Stopped Early: Giving Immunotherapy Before Targeted Rx Improves Survival in Advanced Melanoma

    More people with advanced melanoma survive for two years or more when they receive a combination of two immunotherapy drugs given before a combination of two targeted therapies, if needed, compared to people who start treatment with targeted therapies. The finding comes from a clinical trial that was stopped early because definitive results became apparent sooner than expected. It provides strong evidence for how best to treat patients with melanoma that has a specific mutation: Immunotherapy is the better initial approach even for people whose tumors have a mutation that could be treated by targeted therapies.

    Category: Story

  • Vascular Defects Appear to Underlie the Progression of Parkinson’s Disease

    In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson’s disease. The finding could help explain an earlier outcome of the same study, in which the drug nilotinib was able to halt motor and nonmotor (cognition and quality of life) decline in the long term.

    Category: Story